|
|
|
|
||
Re: Stifel Nicolaus Rating Disclosure on Tekmira Pharmaceuticals CorporationEgo
I think the Stifel math works out. Prior to the OnCore deal announcement, they were essentially implying that the TKMR market cap target was in the range of $800 million. With the deal, they are saying the combined company market cap target is $1.3 billion. Seems like their math agrees with the merger adding significant value. |
return to message board, top of board |